We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Share Name | Share Symbol | Market | Type | Share ISIN | Share Description |
---|---|---|---|---|---|
Instem Plc | LSE:INS | London | Ordinary Share | GB00B3TQCK30 | ORD 10P |
Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
---|---|---|---|---|---|---|---|---|---|---|
0.00 | 0.00% | 830.00 | - | 0.00 | 01:00:00 |
Industry Sector | Turnover | Profit | EPS - Basic | PE Ratio | Market Cap |
---|---|---|---|---|---|
0 | 0 | N/A | 0 |
Date | Subject | Author | Discuss |
---|---|---|---|
11/1/2016 22:22 | Trading statement due any day? Past few years has been around now. | timtom2 | |
18/12/2015 16:53 | Lovely move today. | timtom2 | |
15/5/2015 12:33 | I bought quite a few in the 130-140p area. They're market leaders in their niche but are subject to pharma R&D cutbacks every so often so have the odd setback. Usually a good opportunity to buy. | wjccghcc | |
15/5/2015 10:04 | Rise in short time from 135p to well over 200p and no postings. A huge contract win. Very strange BB. Just bought in, a small purchase, after over a year watching this one. | greek islander | |
27/2/2015 12:02 | Video interview with CEO Phil Reason Phil Reason, the chief executive of Instem (LON:INS), says he is very excited by the opportunity offered by Centrus-submit solution, which enables non-clinical data to be sent to the FDA by electronically rather than on paper. ‘That’s got a huge potential to reduce the amount of time it takes a regulatory reviewer to complete their review of a regulatory submission and accelerate the pace at which a new drug can come to market,’ Reason explains. Instem’s CEO also discusses the newsflow that he hopes will drive the share price higher. | proactivest | |
20/9/2013 09:19 | Results due Wednesday. | m.t.glass | |
12/7/2013 15:18 | Just sold my lot as I think over extended in the short term however will look to go back in at some point | parvez | |
11/7/2013 15:45 | Looking good, difficult to buy any quantity | tech | |
03/7/2013 07:32 | I did pick these up again and believe that these are set to take off with more positive news | parvez | |
02/7/2013 18:01 | Nice deal guys, look forward to more of these and I'll top up my holding | fastbuck | |
13/5/2013 22:59 | I believe this company is now back on a growth path following positive contract comments made in March, the US Govt deal in February and the Chinese deal in April. Add in the add-on acquisition expanding the product offering and expanding the customer base for cross selling opportunities.On a historic PE of circ 12 I picked up shares today, the first deal of many if the company delivers at interims!! | fastbuck | |
28/2/2013 08:25 | I just sold out at 137 - profit is a profit but am sure will be kicking myself later :) | parvez | |
28/2/2013 08:15 | will it top around 170p today as no stoc available!? | parvez | |
28/2/2013 07:32 | Very interesting company Strong balance sheet with cash of around £2.8m and signing contracts like there's no tomorrow plus this from early Feb this year Mike Harwood, Instem's Senior Vice President, comments, "Client feedback throughout this development project has been extremely positive and has helped to ensure that version 9 is a robust, high quality, fit-for-purpose application for the Tox/Path market. The features included in version 9 are in high demand; numerous clients have committed to upgrading with several more poised to sign shortly." | mirabeau | |
09/1/2012 22:07 | profeet warning | dugganjoe | |
24/3/2011 10:54 | Rating and comment on the shares | ibrahim1962 | |
19/1/2011 22:17 | Trading statement today looks positive. Quiet here also a positive. | choppa | |
17/1/2011 11:04 | An intriguing play added today. | choppa |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions